

Genomic Data¹ and Tissue Specimens at Data Release 8: Incident Breast and Ovarian Cancer²: Sister Study, Overall and 4% Random Subcohort

	DNA extracted ³			GWAS ¹		Methylation ¹		Methylation ¹		Methylation ¹		Blocks		Slides Only	
	Total			Oncoarray		LINE 1		27K		450K		Received ^{4,5}		Received ⁴	
	N	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Sister Study Participants (All)	50,884	19,129	37.6	4,912	9.7	1,035	2.0	1,043	2.0	3,073	6.0	2,399	4.7	256	0.5
Incident Breast Cancer (any type) ⁶	3,804	3,751	98.6	2,372	62.4	377	9.9	391	10.3	1,652	43.4	2,290	60.2	240	6.3
Incident Breast Cancer (DCIS/Invasive) ⁷	3,681	3,654	99.3	2,302	62.5	363	9.9	381	10.4	1,652	44.9	2,253	61.2	234	6.4
Incident Ovarian Cancer ⁸	257	252	98.1	151	58.8	8	3.1	7	2.7	22	8.6	85	33.1	8	3.1
Random Subcohort (4% of Sister Study)⁹	2,036	2,025	99.5	2,021	99.3	312	15.3	311	15.3	1,336	65.6	105	5.2	9	0.4
No Breast Cancer (any type) and No Ovarian Cancer ¹⁰	1,871	1,861	99.5	1,857	99.3	272	14.5	273	14.6	1,222	65.3	N/A		N/A	
Incident Breast Cancer (any type) ¹¹	157	156	99.4	156	99.4	39	24.8	38	24.2	109	69.4	99	63.1	9	5.7
Incident Ovarian Cancer ¹¹	8	8	100.0	8	100.0	1	12.5	0	--	5	62.5	4	50.0	0	0.0
<i>No DCIS/Invasive Breast Cancer and No Ovarian Cancer¹⁰</i>	1,877	1,867	99.5	1,863	99.3	274	14.6	275	14.7	1,223	65.2	N/A		N/A	
<i>Incident DCIS/Invasive Breast Cancer¹¹</i>	151	150	99.3	150	99.3	37	24.5	36	23.8	108	71.5	96	63.6	9	6.0
Other¹²	1,131	1,090	96.4	554	49.0	381	33.7	375	33.2	191	16.9	N/A		N/A	

¹ Table reflects N of samples sent for assay, not N of samples with usable results. Investigator cutoffs will affect N of usable samples. *For study planning, more detailed information is available on request.*

² Ovarian cancer includes fallopian tube and peritoneal cancers

³ DNA extracted as of 11/5/2020. ≥ 5 μ g of DNA in storage.

⁴ Includes tissue samples received through 10/14/2020

⁵ Includes those where only blocks were received and those where both blocks and slides were received

⁶ Includes 1st LCIS/DCIS/Invasive breast cancer. Excludes prevalent breast cancer; breast cancer with unknown timing (incident vs. prevalent); and uncertain breast cancer dx (breast cancer possible but unlikely)

⁷ Includes 1st DCIS/Invasive breast cancer. Excludes LCIS, prevalent DCIS/Invasive breast cancer and all DCIS/Invasive breast cancer with unknown timing (incident vs. prevalent) or uncertain dx (breast cancer possible but unlikely)

⁸ Excludes prevalent ovarian/fallopian tube/peritoneal cancer; ovarian/fallopian tube/peritoneal cancer timing unknown; and ovarian/fallopian tube/peritoneal cancer uncertain

⁹ Included in second sample collection (SCL)

¹⁰ Excludes incident, prevalent, timing unknown and diagnosis uncertain for both breast cancer and ovarian/fallopian tube/peritoneal cancer

¹¹ Includes n=0 with both incident breast cancer and incident ovarian/fallopian tube/peritoneal cancer. Excludes prevalent, timing unknown and diagnosis uncertain cases

¹² DNA extracted for other projects (not in 4% subcohort, neither an incident breast cancer or ovarian/fallopian tube/peritoneal cancer case)